<strong>in</strong>struments <strong>in</strong> crim<strong>in</strong>al justice sett<strong>in</strong>gs. Given <strong>the</strong> heterogeneity <strong>of</strong> symptomspresented by <strong>in</strong>dividuals with co-occurr<strong>in</strong>g disorders, it is unlikely that a s<strong>in</strong>gle<strong>in</strong>strument will be developed to assess <strong>the</strong> full range <strong>of</strong> co-occurr<strong>in</strong>g problems, orto dist<strong>in</strong>guish <strong>in</strong>dividuals with co-occurr<strong>in</strong>g disorders from those who have onlymental or substance use disorders (Osher & K<strong>of</strong>oed, 1989).An <strong>in</strong>tegrated approach for assessment <strong>of</strong> co-occurr<strong>in</strong>g disorders <strong>in</strong> <strong>the</strong> justicesystem should <strong>in</strong>clude a comprehensive review <strong>of</strong> mental <strong>and</strong> substance usedisorders <strong>and</strong> an exam<strong>in</strong>ation <strong>of</strong> crim<strong>in</strong>al justice history <strong>and</strong> status. Anassessment should be conducted <strong>of</strong> each disorder <strong>in</strong> addition to an assessment<strong>of</strong> <strong>the</strong> <strong>in</strong>teractive effects <strong>of</strong> <strong>the</strong> disorders. Several previously described screen<strong>in</strong>g<strong>in</strong>struments are <strong>of</strong>ten used as part <strong>of</strong> an assessment battery to exam<strong>in</strong>e specializedareas (e.g., diagnostic symptoms <strong>of</strong> alcohol <strong>and</strong>/or drug abuse) related to cooccurr<strong>in</strong>gdisorders. More comprehensive <strong>in</strong>struments for assess<strong>in</strong>g co-occurr<strong>in</strong>gdisorders are described <strong>in</strong> Appendices I, J, K, <strong>and</strong> L, <strong>in</strong>clud<strong>in</strong>g <strong>the</strong> PsychiatricResearch Interview for Substance <strong>and</strong> Mental <strong>Disorders</strong> (PRISM), <strong>the</strong> AddictionSeverity Index–Fifth Version (ASI-V5), <strong>the</strong> M<strong>in</strong>nesota Multiphasic PersonalityInventory-2 (MMPI-2), <strong>the</strong> Millon Cl<strong>in</strong>ical Multiaxial Inventory-III (MCMI-III),<strong>and</strong> <strong>the</strong> Personality <strong>Assessment</strong> Inventory (PAI).These assessment <strong>in</strong>struments differ significantly <strong>in</strong> <strong>the</strong>ir coverage <strong>of</strong> areasrelated to mental <strong>and</strong> substance use disorders, validation for use <strong>in</strong> community<strong>and</strong> crim<strong>in</strong>al justice sett<strong>in</strong>gs, cost, scor<strong>in</strong>g procedures, <strong>and</strong> tra<strong>in</strong><strong>in</strong>g required foradm<strong>in</strong>istration. O<strong>the</strong>r considerations <strong>in</strong> select<strong>in</strong>g assessment <strong>in</strong>struments are <strong>the</strong>level <strong>of</strong> staff tra<strong>in</strong><strong>in</strong>g, certification, <strong>and</strong> expertise required. Case manager rat<strong>in</strong>gs,<strong>in</strong>formation from collateral <strong>in</strong>formants (e.g., family members), <strong>and</strong> archival (e.g.,crim<strong>in</strong>al history) <strong>in</strong>formation should also be considered dur<strong>in</strong>g assessment <strong>of</strong> cooccurr<strong>in</strong>gdisorders.Appendices I, J, K, <strong>and</strong> L provide a detailed review <strong>and</strong> analysis <strong>of</strong> availableassessment <strong>in</strong>struments for co-occurr<strong>in</strong>g disorders. Based on <strong>the</strong> critical evaluation<strong>of</strong> <strong>the</strong>se <strong>in</strong>struments, <strong>the</strong> follow<strong>in</strong>g comb<strong>in</strong>ation <strong>of</strong> <strong>in</strong>struments is recommendedto assess for co-occurr<strong>in</strong>g disorders <strong>in</strong> justice sett<strong>in</strong>gs:1. Ei<strong>the</strong>r <strong>the</strong> Psychiatric Research Interview for Substance <strong>and</strong> Mental<strong>Disorders</strong> (PRISM),(or)2. A comb<strong>in</strong>ation <strong>of</strong> ei<strong>the</strong>r <strong>the</strong> M<strong>in</strong>nesota Multiphasic PersonalityInventory-2 (MMPI-2), <strong>the</strong> Millon Cl<strong>in</strong>ical Multiaxial Inventory-III(MCMI-III), or <strong>the</strong> Personality <strong>Assessment</strong> Inventory (PAI) to exam<strong>in</strong>emental disorders,(<strong>and</strong>)The Addiction Severity Index (ASI) to exam<strong>in</strong>e substance use disorders.The PRISM requires approximately 90 m<strong>in</strong>utes to adm<strong>in</strong>ister, <strong>and</strong> <strong>the</strong> comb<strong>in</strong>edapproach us<strong>in</strong>g a separate mental health <strong>and</strong> substance use <strong>in</strong>strument requires37
approximately two hours. Ei<strong>the</strong>r <strong>the</strong> DIS-IV or SCID-IV may be used to providemore precise diagnostic <strong>in</strong>formation, as needed, if additional time is available.Staff Tra<strong>in</strong><strong>in</strong>gThose work<strong>in</strong>g <strong>in</strong> crim<strong>in</strong>al justice sett<strong>in</strong>gs are <strong>of</strong>ten <strong>in</strong>adequately tra<strong>in</strong>ed <strong>in</strong>identification, assessment, diagnosis, treatment, <strong>and</strong> supervision <strong>of</strong> <strong>in</strong>dividualswith co-occurr<strong>in</strong>g disorders. For example, screen<strong>in</strong>gs are <strong>of</strong>ten conducted bystaff who lack considerable tra<strong>in</strong><strong>in</strong>g or experience related to mental or substanceuse disorders <strong>and</strong> who may be unfamiliar with related treatment services for<strong>the</strong>se disorders. In recent years, a specialized base <strong>of</strong> knowledge <strong>and</strong> set <strong>of</strong> skillshave been developed for work<strong>in</strong>g with justice-<strong>in</strong>volved <strong>in</strong>dividuals who have cooccurr<strong>in</strong>gdisorders. Tra<strong>in</strong><strong>in</strong>g <strong>in</strong> <strong>the</strong>se areas should be provided for all staff whoare <strong>in</strong>volved <strong>in</strong> screen<strong>in</strong>g <strong>and</strong> assess<strong>in</strong>g for co-occurr<strong>in</strong>g disorders <strong>in</strong> <strong>the</strong> justicesystem.Specialized tra<strong>in</strong><strong>in</strong>g <strong>in</strong> crim<strong>in</strong>al justice sett<strong>in</strong>gs should be considered <strong>in</strong> each <strong>of</strong> <strong>the</strong>follow<strong>in</strong>g areas:•y Prevalence, course, signs, <strong>and</strong> symptoms <strong>of</strong> co-occurr<strong>in</strong>g disorders•y Interaction <strong>of</strong> symptoms <strong>of</strong> mental <strong>and</strong> substance use disorders•y Strategies for enhanc<strong>in</strong>g accuracy <strong>of</strong> screen<strong>in</strong>g <strong>and</strong> assessment <strong>in</strong>formationamong those who have co-occurr<strong>in</strong>g disorders•y Use <strong>of</strong> specialized screen<strong>in</strong>g <strong>and</strong> assessment <strong>in</strong>struments•y Integrated treatment approaches <strong>and</strong> o<strong>the</strong>r evidence-based practices•y Supervision <strong>and</strong> sanction approaches for <strong>in</strong>dividuals with co-occurr<strong>in</strong>gdisorders•y Specialized services available <strong>in</strong> <strong>the</strong> community for justice-<strong>in</strong>volved<strong>in</strong>dividuals with co-occurr<strong>in</strong>g disorders, <strong>and</strong> procedures for <strong>in</strong>itiat<strong>in</strong>greferrals for assessment <strong>and</strong> treatment services.38
- Page 1: Screening and Assessmentof Co-Occur
- Page 5 and 6: Screening Instruments for Co-Occurr
- Page 12 and 13: daunting task, and often requires t
- Page 14 and 15: Importance of Screening and Assessm
- Page 16 and 17: •y•y•y•y•y•y•y•y•
- Page 18 and 19: Developing a Comprehensive Screenin
- Page 20 and 21: •y•y•y•y•y•y•y•y•
- Page 22 and 23: These areas of cognitive and behavi
- Page 24 and 25: •y•y•y•y•y•y•y•yAlc
- Page 26 and 27: frequency of drug testing may be ta
- Page 28 and 29: offer expanded tests that also incl
- Page 30 and 31: self-disclosure of mental health or
- Page 32 and 33: should be determined by the severit
- Page 34 and 35: Special Clinical Issues in Screenin
- Page 36: suicide screening is important for
- Page 39 and 40: Maintaininga staff ofdiverse ethnic
- Page 41 and 42: The MHSF-III and the GAIN-SS were f
- Page 43 and 44: Key Information to Include in Asses
- Page 45: •y•y`` Vocational and education
- Page 49 and 50: Texas Christian University Drug Scr
- Page 51 and 52: & Cirimele, 2006). Hair testing can
- Page 53 and 54: Appendix B: Screening Instruments f
- Page 55 and 56: Suicide Probability Scale (SPS)The
- Page 57 and 58: Positive Features•y•y•yThe TS
- Page 59 and 60: Appendix D: Screening Instruments f
- Page 61 and 62: Positive Features•y•y•y•yTh
- Page 63 and 64: Positive Features•y•y•y•y
- Page 65 and 66: Appendix F: Screening Instruments T
- Page 67 and 68: Availability and CostThe CAMH-CDS i
- Page 69 and 70: and one Axis II disorder (antisocia
- Page 71 and 72: Appendix G: Screening Instruments f
- Page 73 and 74: prior hospitalization for mental he
- Page 75 and 76: •yThe instrument has been used wi
- Page 77 and 78: •yThe instrument has not been use
- Page 79 and 80: Appendix H: Screening Instruments f
- Page 81 and 82: Positive Features•y•y•y•y
- Page 83 and 84: have you felt you ought to Cut down
- Page 85 and 86: Concerns•y•y•yThe DALI was de
- Page 87 and 88: •y•y•y•y•y•y•ywith sc
- Page 89 and 90: Concerns80•y•y•y•y•y•y
- Page 91 and 92: Concerns•y The validity of the SS
- Page 93 and 94: Appendix I: Recommended Instruments
- Page 95 and 96: Concerns•y•y•y•yReliabiliti
- Page 97 and 98:
•y•y•y•yScales and profile
- Page 99 and 100:
•y•yand non-interpretable resul
- Page 101 and 102:
Appendix L: Assessment Instruments
- Page 103 and 104:
Philadelphia, PA 19106, (215) 399-0
- Page 105 and 106:
treatment setting. Treatment progra
- Page 107 and 108:
Concerns•y•y•yThe CIDI is qui
- Page 109 and 110:
•y•y•yThe PDSQ has been used
- Page 111 and 112:
Both a Research Version and a Clini
- Page 113 and 114:
104
- Page 115 and 116:
Bastiaens, L., Riccardi, K., & Sakh
- Page 117 and 118:
Carey, K. B., Carey, M. P., & Chand
- Page 119 and 120:
Demmel, R., Beck, B., Richter, D.,
- Page 121 and 122:
Gray, B. T. (2001). A factor analyt
- Page 123 and 124:
Kessler, R. C., Wittchen, H. U., Ab
- Page 125 and 126:
McLellan, A. T., Cacciola, J. S., &
- Page 127 and 128:
Nochajski, T. H., & Stasiewicz, P.
- Page 129 and 130:
Rollnick, H., Heather, N., Gold, R.
- Page 131 and 132:
Teitelbaum L. M., & Mullen, B. (200
- Page 133:
Zimmerman, M., & Sheeran, T. (2003)